Current filters:


1 to 9 of 22 results

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune


Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone


US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

Strong new data for InterMune’s Esbriet sees the firm’s stock rocket


US biotech firm InterMune has released top-line data from ASCEND, a Phase III trial evaluating pirfenidone…

BiotechnologyEsbrietInterMuneResearchRespiratory and Pulmonary

Ireland's HSE to reimburse InterMune's Esbriet for IPF


US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Pricing and reimbursement conditions for InterMune's Esbriet in Italy


US biotech firm InterMune (Nasdaq: ITMN) says that the board of the Italian Drug Agency (AIFA) has approved…

BiotechnologyEsbrietEuropeInterMunePricingRespiratory and Pulmonary

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData


Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

1 to 9 of 22 results

Back to top